Edarbyclor - (40 mg/12.5 mg and 40 mg/25 mg ; Tablet)

Generic Name	Azilsartan Medoxomil and Chlorthalidone	Innovator	Azurity (Arbor)
Dosage	40 mg/12.5 mg and 40 mg/25 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Edarbyclor is an angiotensin II receptor blocker (ARB) and a thiazidelike diuretic combination product indicated for the treatment of hypertension, to lower blood pressure: • In patients not adequately controlled with monotherapy • As initial therapy in patients likely to need multiple drugs to help achieve blood pressure goals
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** / *********	*** **, ****	*******	********* ********	*** ****** *** ****
***** ******	** / **	*** **, ****	*******	****	*** ****** *** ****
****	** / **	*** **, ****	*******	****	******* *** **** *** *** ****

Chronology Of Events